Organon & Co. Announces Shareholder Approval of Sun Pharma Merger

What Happened
Organon & Co. (OGN) filed an 8-K reporting that its special meeting of stockholders on July 23, 2026 approved the Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc. (Merger Agreement dated April 26, 2026). The vote was held virtually; as of the June 15, 2026 record date there were 262,609,433 shares outstanding and 195,675,859 shares (74.51%) were represented, constituting a quorum. If completed, the Merger will result in Organon surviving as a wholly owned subsidiary of Sun Pharma USA.

Key Details

• Special meeting date: July 23, 2026 (virtual). Record date: June 15, 2026.
• Shares outstanding: 262,609,433. Shares represented/voted: 195,675,859 (74.51%).
• Proposal 1 (Adopt Merger Agreement) — Votes For: 192,776,552; Against: 2,573,118; Abstain: 326,189; Broker non-votes: 0.
• Proposal 2 (Advisory approval of executive compensation tied to the Merger) — Votes For: 185,141,986; Against: 9,553,830; Abstain: 980,043; Broker non-votes: 0. (This was a non‑binding, advisory vote.)

Why It Matters
Shareholder approval of the Merger Agreement is a major procedural step toward completing the transaction and will change Organon’s ownership and governance if the deal closes: the company is slated to become a wholly owned subsidiary of Sun Pharma USA. The advisory vote in favor of merger-related executive compensation signals shareholder support for the proposed compensation arrangements, though that vote is not binding. Retail investors should note the approval itself—while material—does not by itself confirm closing timing or final terms beyond those disclosed; further filings will report additional closing conditions and timing.